We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 18, 2020

Capivasertib + Fulvestrant Improves Activity and Tolerability in AKT1E17K-Mutant, ER+ MBC

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Clin. Cancer Res 2020 Apr 20;[EPub Ahead of Print], LM Smyth, K Tamura, M Oliveira, EM Ciruelos, IA Mayer, MP Sablin, L Biganzoli, HJ Ambrose, J Ashton, A Barnicle, DD Cashell, C Corcoran, EC de Bruin, A Foxley, J Hauser, JPO Lindemann, R Maudsley, R McEwen, M Moschetta, M Pass, V Rowlands, G Schiavon, U Banerji, M Scaltriti, BS Taylor, S Chandarlapaty, J Baselga, DM Hyman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading